Related Experiment Videos
In diabetes, treat hidden heart disease
1Division of Endocrinology, Diabetes, and Hypertension, University of California, Los Angeles 90095, USA.
Insights
Diabetic and prediabetic patients have hidden cardiovascular disease. Angiotensin-converting-enzyme (ACE) inhibitors and aggressive management of hypertension and dyslipidemia are crucial for reducing cardiovascular risks in these populations.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetic and prediabetic individuals exhibit abnormal vascular reactivity, suggesting underlying occult cardiovascular disease.
- Cardiovascular complications and diabetes-related issues are significant concerns in these patient groups.
Purpose of the Study:
- To highlight the cardiovascular risks associated with diabetes and prediabetes.
- To emphasize the benefits of specific pharmacological interventions and management strategies.
Main Methods:
- Review of existing literature on vascular reactivity in diabetes and prediabetes.
- Analysis of the impact of Angiotensin-converting-enzyme (ACE) inhibitors on cardiovascular events and diabetes progression.
- Evaluation of the role of hypertension and dyslipidemia management.
Main Results:
- ACE inhibitors demonstrate significant benefits in reducing cardiovascular events and diabetes complications in diabetic patients.
- ACE inhibitors also lower the risk of developing type 2 diabetes in prediabetic individuals.
- Aggressive management of hypertension and dyslipidemia is essential for mitigating heart disease risk.
Conclusions:
- Patients with diabetes and prediabetes should be considered at high risk for cardiovascular disease.
- ACE inhibitors are a key therapeutic option for managing cardiovascular and diabetes-related risks.
- Comprehensive management including blood pressure and lipid control is vital for improving outcomes.
Abstract:
Both diabetic and prediabetic patients have abnormal vascular reactivity and should be considered to have occult cardiovascular disease. Angiotensin-converting-enzyme (ACE) inhibitors are particularly beneficial in diabetes because they reduce the incidence of both cardiovascular events and diabetes-related complications. In prediabetic patients, ACE inhibitors also reduce the risk of a new diagnosis of type 2 diabetes. Managing hypertension is even more beneficial for diabetic patients than for nondiabetic patients. To further reduce the risk of heart disease in patients with diabetes or prediabetes, dyslipidemia should also be treated aggressively.